Skip to main content

Geospiza Reels in SBIR Grant

NEW YORK (GenomeWeb News) - Geospiza has won a Small Business Innovation Research grant from the National Human Genome Research Institute to fund genomic analysis software development, the company said today.

The Seattle-based company plans to use the Phase I grant to develop software that will be used in detecting rare mutations found in certain cancer types and to help make treatment decisions.

"New sequencing technologies are advancing at a significant pace and the instrument vendors are making tremendous progress in developing a wide range of applications that will change how we examine gene expression and study how variations in DNA sequences cause disease and impact health," Geospiza CSO Todd Smith said in a statement.

"This award will help us conduct important research to develop new methods to support resequencing applications," he added.

Geospiza did not disclose the amount of the grant, but standard Phase I SBIR awards last up to six months and grant as much as $100,000.

The Scan

And For Adolescents

The US Food and Drug Administration has authorized the Pfizer-BioNTech SARS-CoV-2 vaccine for children between the ages of 12 and 15 years old.

Also of Concern to WHO

The Wall Street Journal reports that the World Health Organization has classified the SARS-CoV-2 variant B.1.617 as a "variant of concern."

Test for Them All

The New York Times reports on the development of combined tests for SARS-CoV-2 and other viruses like influenza.

PNAS Papers on Oral Microbiome Evolution, Snake Toxins, Transcription Factor Binding

In PNAS this week: evolution of oral microbiomes among hominids, comparative genomic analysis of snake toxins, and more.